One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders
Jonas JW Kuiper, Jörg C Prinz, Efstratios Stratikos, Piotr Kuśnierczyk, Akiko Arakawa, Sebastian Springer, Dillon Mintoff, Ivan Padjen, Russka Shumnalieva, Seçil Vural, Ina Kötter, Marleen G van de Sande, Ayşe Boyvat, Joke H de Boer, George Bertsias, Niek de Vries, Charlotte LM Krieckaert, Inês Leal, Nataša Vidovi� Valentin�i�, Ilknur Tugal-Tutkun, Hanane el Khaldi Ahanach, Félicie Costantino, Simon Glatigny, Danijela Mrazovac Zimak, Fabian Lötscher, Floor G Kerstens, Marija Bakula, Elsa Viera Sousa, Peter Böhm, Kees Bosman, Tony J Kenna, Simon J Powis, Maxime Breban, Ahmet Gul, John Bowes, Rik JU Lories, Johannes Nowatzky, Gerrit Jan Wolbink, Dennis G McGonagle, Franktien Turkstra
doi : 10.1136/ard-2022-222852
July 2023 - Volume 82 - 7
The ‘MHC-I (major histocompatibility complex class I)-opathy’ concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Behçet’s disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8+T cells in the pathogenesis.
What is a response in randomised controlled trials in giant cell arteritis?
Christian Dejaco, Sofia Ramiro, Zahi Touma, Milena Bond, Medha Soowamber, Catalina Sanchez-Alvarez, Carol A Langford
doi : 10.1136/ard-2022-223751
Glucocorticoids (GCs) are the gold standard for treatment of giant cell arteritis (GCA); however, there is a need for studies on GC-sparing agents, given that up to 85% of patients receiving GC only develop adverse events. Previous randomised controlled trials (RCTs) have applied different primary endpoints, limiting the comparison of treatment effects in meta-analyses and creating an undesired heterogeneity of outcomes.
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
Lars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto, Jose Rivas, Birgitta Benda
doi : 10.1136/ard-2022-223715
Objectives Based on primary results from ORAL Surveillance, an event-driven clinical trial of risk-enriched patients, identify subpopulations with different relative risk (ie, ‘high-risk’ and ‘low-risk’) with tofacitinib versus tumour necrosis factor inhibitors (TNFi).
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
Viking Huss, Hannah Bower, Karin Hellgren, Thomas Frisell, Johan Askling
doi : 10.1136/ard-2022-223636
Objective Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice.
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
Anne R Bass, Noha Abdel-Wahab, Pankti D Reid, Jeffrey A Sparks, Cassandra Calabrese, Deanna P Jannat-Khah, Nilasha Ghosh, Divya Rajesh, Carlos Andres Aude, Lydia Gedmintas, Lindsey MacFarlane, Senada Arabelovic, Adewunmi Falohun, Komal Mushtaq, Farah Al Haj, Adi Diab, Ami A Shah, Clifton O Bingham, Karmela Kim Chan, Laura C Cappelli
doi : 10.1136/ard-2023-223885
Objectives To compare the safety and effectiveness of biologic and conventional disease-modifying antirheumatic drugs (DMARDs) for immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA).
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes
May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J Fritzler, Katherine A Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J Wallace, David Alan Isenberg, Anisur Rahman, Joan T Merrill, Paul R Fortin, Dafna D Gladman, Ian N Bruce, Michelle Petri, Ellen M Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jönsen, Graciela S Alarcón, Ronald F van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Søren Jacobsen, Christine Peschken, Diane L Kamen, Anca Askanase, Jill P Buyon, David Sontag, Karen H Costenbader
doi : 10.1136/ard-2022-223808
Objectives A novel longitudinal clustering technique was applied to comprehensive autoantibody data from a large, well-characterised, multinational inception systemic lupus erythematosus (SLE) cohort to determine profiles predictive of clinical outcomes.
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
Rona M Smith, Rachel B Jones, Ulrich Specks, Simon Bond, Marianna Nodale, Reem Al-jayyousi, Jacqueline Andrews, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Vimal Derebail, Tim Doulton, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz-Singer, Lorraine Harper, Toshiko Ito-Ihara, Nader Khalidi, Rainer Klocke, Curry Koening, Yoshinori Komagata, Carol Langford, Peter Lanyon, Raashid Luqmani, Carol McAlear, Larry W Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Rennie L Rhee, Robert Spiera, Antoine G Sreih, Vladamir Tesar, Giles Walters, Caroline Wroe, David Jayne, Peter A Merkel
doi : 10.1136/ard-2022-223559
Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality. The RITAZAREM trial compared the efficacy of repeat-dose rituximab to daily oral azathioprine for prevention of relapse in patients with relapsing AAV in whom remission was reinduced with rituximab.
Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunity
Nienke Oskam, Pleuni Ooijevaar-De Heer, Dorien Kos, Jorn Jeremiasse, Laurette van Boheemen, Gwenny M Verstappen, Frans G M Kroese, Dirkjan van Schaardenburg, Gertjan Wolbink, Theo Rispens
doi : 10.1136/ard-2023-223901
Background Rheumatoid factors (RF) are one of the hallmark autoantibodies characteristic of rheumatoid arthritis (RA), and are frequently observed in other diseases and in healthy individuals. RFs comprise multiple subtypes with different specificities towards the constant region of human IgG. Studies indicate that these patterns differ between naturally occurring RFs and RFs associated with disease. However, individual specificities characteristic of either have not been clearly defined.
Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults
Zachary S Wallace, Gandarvaka Miles, Ekaterina Smolkina, Natalia Petruski-Ivleva, Duane Madziva, Claire Cook, Xiaoqing Fu, Yuqing Zhang, John H Stone, Hyon K Choi
doi : 10.1136/ard-2023-223950
Background IgG4-related disease (IgG4-RD) is an immune-mediated condition that can affect nearly any organ or anatomic site. We sought to describe the epidemiology of IgG4-RD in the USA.
EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders
Jonas JW Kuiper, Jörg C Prinz, Efstratios Stratikos, Piotr Kuśnierczyk, Akiko Arakawa, Sebastian Springer, Dillon Mintoff, Ivan Padjen, Russka Shumnalieva, Seçil Vural, Ina Kötter, Marleen G van de Sande, Ayşe Boyvat, Joke H de Boer, George Bertsias, Niek de Vries, Charlotte LM Krieckaert, Inês Leal, Nataša Vidovi� Valentin�i�, Ilknur Tugal-Tutkun, Hanane el Khaldi Ahanach, Félicie Costantino, Simon Glatigny, Danijela Mrazovac Zimak, Fabian Lötscher, Floor G Kerstens, Marija Bakula, Elsa Viera Sousa, Peter Böhm, Kees Bosman, Tony J Kenna, Simon J Powis, Maxime Breban, Ahmet Gul, John Bowes, Rik JU Lories, Johannes Nowatzky, Gerrit Jan Wolbink, Dennis G McGonagle, Franktien Turkstra
doi : 10.1136/ard-2022-222852
July 2023 - Volume 82 - 7
The ‘MHC-I (major histocompatibility complex class I)-opathy’ concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Behçet’s disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8+T cells in the pathogenesis.
What is a response in randomised controlled trials in giant cell arteritis?
Christian Dejaco, Sofia Ramiro, Zahi Touma, Milena Bond, Medha Soowamber, Catalina Sanchez-Alvarez, Carol A Langford
doi : 10.1136/ard-2022-223751
Glucocorticoids (GCs) are the gold standard for treatment of giant cell arteritis (GCA); however, there is a need for studies on GC-sparing agents, given that up to 85% of patients receiving GC only develop adverse events. Previous randomised controlled trials (RCTs) have applied different primary endpoints, limiting the comparison of treatment effects in meta-analyses and creating an undesired heterogeneity of outcomes.
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
Lars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto, Jose Rivas, Birgitta Benda
doi : 10.1136/ard-2022-223715
Objectives Based on primary results from ORAL Surveillance, an event-driven clinical trial of risk-enriched patients, identify subpopulations with different relative risk (ie, ‘high-risk’ and ‘low-risk’) with tofacitinib versus tumour necrosis factor inhibitors (TNFi).
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
Viking Huss, Hannah Bower, Karin Hellgren, Thomas Frisell, Johan Askling
doi : 10.1136/ard-2022-223636
Objective Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice.
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
Anne R Bass, Noha Abdel-Wahab, Pankti D Reid, Jeffrey A Sparks, Cassandra Calabrese, Deanna P Jannat-Khah, Nilasha Ghosh, Divya Rajesh, Carlos Andres Aude, Lydia Gedmintas, Lindsey MacFarlane, Senada Arabelovic, Adewunmi Falohun, Komal Mushtaq, Farah Al Haj, Adi Diab, Ami A Shah, Clifton O Bingham, Karmela Kim Chan, Laura C Cappelli
doi : 10.1136/ard-2023-223885
Objectives To compare the safety and effectiveness of biologic and conventional disease-modifying antirheumatic drugs (DMARDs) for immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA).
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes
May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J Fritzler, Katherine A Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J Wallace, David Alan Isenberg, Anisur Rahman, Joan T Merrill, Paul R Fortin, Dafna D Gladman, Ian N Bruce, Michelle Petri, Ellen M Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jönsen, Graciela S Alarcón, Ronald F van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Søren Jacobsen, Christine Peschken, Diane L Kamen, Anca Askanase, Jill P Buyon, David Sontag, Karen H Costenbader
doi : 10.1136/ard-2022-223808
Objectives A novel longitudinal clustering technique was applied to comprehensive autoantibody data from a large, well-characterised, multinational inception systemic lupus erythematosus (SLE) cohort to determine profiles predictive of clinical outcomes.
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
Rona M Smith, Rachel B Jones, Ulrich Specks, Simon Bond, Marianna Nodale, Reem Al-jayyousi, Jacqueline Andrews, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Vimal Derebail, Tim Doulton, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz-Singer, Lorraine Harper, Toshiko Ito-Ihara, Nader Khalidi, Rainer Klocke, Curry Koening, Yoshinori Komagata, Carol Langford, Peter Lanyon, Raashid Luqmani, Carol McAlear, Larry W Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Rennie L Rhee, Robert Spiera, Antoine G Sreih, Vladamir Tesar, Giles Walters, Caroline Wroe, David Jayne, Peter A Merkel
doi : 10.1136/ard-2022-223559
Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality. The RITAZAREM trial compared the efficacy of repeat-dose rituximab to daily oral azathioprine for prevention of relapse in patients with relapsing AAV in whom remission was reinduced with rituximab.
Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunity
Nienke Oskam, Pleuni Ooijevaar-De Heer, Dorien Kos, Jorn Jeremiasse, Laurette van Boheemen, Gwenny M Verstappen, Frans G M Kroese, Dirkjan van Schaardenburg, Gertjan Wolbink, Theo Rispens
doi : 10.1136/ard-2023-223901
Background Rheumatoid factors (RF) are one of the hallmark autoantibodies characteristic of rheumatoid arthritis (RA), and are frequently observed in other diseases and in healthy individuals. RFs comprise multiple subtypes with different specificities towards the constant region of human IgG. Studies indicate that these patterns differ between naturally occurring RFs and RFs associated with disease. However, individual specificities characteristic of either have not been clearly defined.
Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults
Zachary S Wallace, Gandarvaka Miles, Ekaterina Smolkina, Natalia Petruski-Ivleva, Duane Madziva, Claire Cook, Xiaoqing Fu, Yuqing Zhang, John H Stone, Hyon K Choi
doi : 10.1136/ard-2023-223950
Background IgG4-related disease (IgG4-RD) is an immune-mediated condition that can affect nearly any organ or anatomic site. We sought to describe the epidemiology of IgG4-RD in the USA.
EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders
Jonas JW Kuiper, Jörg C Prinz, Efstratios Stratikos, Piotr Kuśnierczyk, Akiko Arakawa, Sebastian Springer, Dillon Mintoff, Ivan Padjen, Russka Shumnalieva, Seçil Vural, Ina Kötter, Marleen G van de Sande, Ayşe Boyvat, Joke H de Boer, George Bertsias, Niek de Vries, Charlotte LM Krieckaert, Inês Leal, Nataša Vidovi� Valentin�i�, Ilknur Tugal-Tutkun, Hanane el Khaldi Ahanach, Félicie Costantino, Simon Glatigny, Danijela Mrazovac Zimak, Fabian Lötscher, Floor G Kerstens, Marija Bakula, Elsa Viera Sousa, Peter Böhm, Kees Bosman, Tony J Kenna, Simon J Powis, Maxime Breban, Ahmet Gul, John Bowes, Rik JU Lories, Johannes Nowatzky, Gerrit Jan Wolbink, Dennis G McGonagle, Franktien Turkstra
doi : 10.1136/ard-2022-222852
July 2023 - Volume 82 - 7
The ‘MHC-I (major histocompatibility complex class I)-opathy’ concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Behçet’s disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8+T cells in the pathogenesis.
What is a response in randomised controlled trials in giant cell arteritis?
Christian Dejaco, Sofia Ramiro, Zahi Touma, Milena Bond, Medha Soowamber, Catalina Sanchez-Alvarez, Carol A Langford
doi : 10.1136/ard-2022-223751
Glucocorticoids (GCs) are the gold standard for treatment of giant cell arteritis (GCA); however, there is a need for studies on GC-sparing agents, given that up to 85% of patients receiving GC only develop adverse events. Previous randomised controlled trials (RCTs) have applied different primary endpoints, limiting the comparison of treatment effects in meta-analyses and creating an undesired heterogeneity of outcomes.
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
Lars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto, Jose Rivas, Birgitta Benda
doi : 10.1136/ard-2022-223715
Objectives Based on primary results from ORAL Surveillance, an event-driven clinical trial of risk-enriched patients, identify subpopulations with different relative risk (ie, ‘high-risk’ and ‘low-risk’) with tofacitinib versus tumour necrosis factor inhibitors (TNFi).
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
Viking Huss, Hannah Bower, Karin Hellgren, Thomas Frisell, Johan Askling
doi : 10.1136/ard-2022-223636
Objective Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice.
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
Anne R Bass, Noha Abdel-Wahab, Pankti D Reid, Jeffrey A Sparks, Cassandra Calabrese, Deanna P Jannat-Khah, Nilasha Ghosh, Divya Rajesh, Carlos Andres Aude, Lydia Gedmintas, Lindsey MacFarlane, Senada Arabelovic, Adewunmi Falohun, Komal Mushtaq, Farah Al Haj, Adi Diab, Ami A Shah, Clifton O Bingham, Karmela Kim Chan, Laura C Cappelli
doi : 10.1136/ard-2023-223885
Objectives To compare the safety and effectiveness of biologic and conventional disease-modifying antirheumatic drugs (DMARDs) for immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA).
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes
May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J Fritzler, Katherine A Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J Wallace, David Alan Isenberg, Anisur Rahman, Joan T Merrill, Paul R Fortin, Dafna D Gladman, Ian N Bruce, Michelle Petri, Ellen M Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jönsen, Graciela S Alarcón, Ronald F van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Søren Jacobsen, Christine Peschken, Diane L Kamen, Anca Askanase, Jill P Buyon, David Sontag, Karen H Costenbader
doi : 10.1136/ard-2022-223808
Objectives A novel longitudinal clustering technique was applied to comprehensive autoantibody data from a large, well-characterised, multinational inception systemic lupus erythematosus (SLE) cohort to determine profiles predictive of clinical outcomes.
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
Rona M Smith, Rachel B Jones, Ulrich Specks, Simon Bond, Marianna Nodale, Reem Al-jayyousi, Jacqueline Andrews, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Vimal Derebail, Tim Doulton, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz-Singer, Lorraine Harper, Toshiko Ito-Ihara, Nader Khalidi, Rainer Klocke, Curry Koening, Yoshinori Komagata, Carol Langford, Peter Lanyon, Raashid Luqmani, Carol McAlear, Larry W Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Rennie L Rhee, Robert Spiera, Antoine G Sreih, Vladamir Tesar, Giles Walters, Caroline Wroe, David Jayne, Peter A Merkel
doi : 10.1136/ard-2022-223559
Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality. The RITAZAREM trial compared the efficacy of repeat-dose rituximab to daily oral azathioprine for prevention of relapse in patients with relapsing AAV in whom remission was reinduced with rituximab.
Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunity
Nienke Oskam, Pleuni Ooijevaar-De Heer, Dorien Kos, Jorn Jeremiasse, Laurette van Boheemen, Gwenny M Verstappen, Frans G M Kroese, Dirkjan van Schaardenburg, Gertjan Wolbink, Theo Rispens
doi : 10.1136/ard-2023-223901
Background Rheumatoid factors (RF) are one of the hallmark autoantibodies characteristic of rheumatoid arthritis (RA), and are frequently observed in other diseases and in healthy individuals. RFs comprise multiple subtypes with different specificities towards the constant region of human IgG. Studies indicate that these patterns differ between naturally occurring RFs and RFs associated with disease. However, individual specificities characteristic of either have not been clearly defined.
Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults
Zachary S Wallace, Gandarvaka Miles, Ekaterina Smolkina, Natalia Petruski-Ivleva, Duane Madziva, Claire Cook, Xiaoqing Fu, Yuqing Zhang, John H Stone, Hyon K Choi
doi : 10.1136/ard-2023-223950
Background IgG4-related disease (IgG4-RD) is an immune-mediated condition that can affect nearly any organ or anatomic site. We sought to describe the epidemiology of IgG4-RD in the USA.
